Core Viewpoint - Junshi Biosciences (01877) announced that its controlling shareholder and chairman, Mr. Xiong Jun, has increased his shareholding in the company through the Shanghai Stock Exchange, acquiring a total of 100,000 A-shares, which represents approximately 0.01% of the company's total share capital, with a total transaction amount of RMB 3.8384 million. The share acquisition plan is not yet completed, and Mr. Xiong will continue to increase his holdings as per the plan during the implementation period [1]. Summary by Categories - Shareholding Increase: Mr. Xiong Jun has cumulatively acquired 100,000 A-shares, amounting to 0.01% of the total share capital of Junshi Biosciences [1]. - Transaction Details: The total amount spent on this share acquisition is RMB 3.8384 million [1]. - Future Plans: The share acquisition plan is still ongoing, and Mr. Xiong intends to continue purchasing shares in accordance with the related plan [1].

Group 1 - The core point of the article is that Junshi Biosciences (01877) announced that its controlling shareholder and chairman, Mr. Xiong Jun, has increased his shareholding in the company [1] - Mr. Xiong Jun has cumulatively acquired 100,000 A-shares through the Shanghai Stock Exchange, representing approximately 0.01% of the company's total share capital [1] - The total transaction amount for this share acquisition is approximately RMB 3.8384 million [1] Group 2 - The share acquisition plan is not yet fully implemented, and Mr. Xiong Jun intends to continue purchasing shares in accordance with the relevant plan during the implementation period [1]

格隆汇2月10日丨君实生物(01877.HK)公告，上海君实生物医药科技股份有限公司控股股东、实际控制 人之一兼董事长熊俊拟自2025年4月12日起12个月内，通过上海证券交易所交易系统与香港联合交易所 有限公司允许的方式(包括但不限于集中竞价和大宗交易等方式)增持公司A股股份及H股股份，合计增 持金额不低于人民币1亿元，其中A股增持金额不低于人民币5,000万元。 截至本公告披露日，熊俊通过上海证券交易所系统以集中竞价方式累计增持公司A股股份10万股，约占 公司总股本的0.01%，累计成交总额为人民币383.84万元。本次增持计划尚未实施完毕，熊俊将继续按 照相关增持计划，在增持计划实施期间内择机增持公司股份。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海 君實生物醫藥科技股份有限公司關於控股股東、實際控制人之一兼董事長增持股 份進展公告》，僅供參閱。 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2026年2月10日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 （股份代號：1877） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 证券代码：688180 证券简称：君实生 ...

上海君实生物医药科技股份有限公司 关于控股股东、实际控制人之一兼董事长 增持股份进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 证券代码：688180 证券简称：君实生物 公告编号：临 2026-004 重要内容提示： 上海君实生物医药科技股份有限公司（以下简称"公司"）控股股东、 实际控制人之一兼董事长熊俊先生拟自 2025 年 4 月 12 日起 12 个月内，通过上 海证券交易所交易系统与香港联合交易所有限公司允许的方式（包括但不限于集 中竞价和大宗交易等方式）增持公司 A 股股份及 H 股股份，合计增持金额不低 于人民币 1 亿元，其中 A 股增持金额不低于人民币 5,000 万元。 截至本公告披露日，熊俊先生通过上海证券交易所系统以集中竞价方式 累计增持公司 A 股股份 100,000 股，约占公司总股本的 0.01%，累计成交总额为 人民币 383.84 万元。本次增持计划尚未实施完毕，熊俊先生将继续按照相关增 持计划，在增持计划实施期间内择机增持公司股份。 本次增持计划可能存在因资本市场 ...

格隆汇2月10日丨君实生物(688180.SH)公布，截至本公告披露日，控股股东、实际控制人之一兼董事长 熊俊先生通过上海证券交易所系统以集中竞价方式累计增持公司A股股份10万股，约占公司总股本的 0.01%，累计成交总额为人民币383.84万元。本次增持计划尚未实施完毕，熊俊先生将继续按照相关增 持计划，在增持计划实施期间内择机增持公司股份。 ...

Core Insights - The Chinese biopharmaceutical industry is at a pivotal moment as it transitions from "scale and speed" to "quality and value" during the end of the 14th Five-Year Plan and the beginning of the 15th Five-Year Plan [1][3] - The company emphasizes the importance of innovation, dual-track development, and value orientation to navigate the challenges and opportunities in 2026 [1][4] Group 1: Industry Transition - The industry is experiencing a transformation focused on quality and value, moving away from previous growth models based on scale and speed [1][3] - The company aims to address the challenges of homogenization and competition by focusing on original innovation and differentiated strategies [3][4] Group 2: Globalization and Market Expansion - The company has established a global commercialization network covering over 80 countries and regions, with products launched in 40 international markets [2] - The strategy includes enhancing local patient access while expanding global partnerships to overcome international market entry barriers [4] Group 3: Innovation and Technology - The company is committed to deepening its innovation in the field of tumor immunotherapy, particularly in addressing PD-(L)1 inhibitor resistance [3] - AI technology is being leveraged to optimize operational efficiency and enhance quality, aligning with the industry's focus on sustainable development [4]

恒生港股通创新药指数是ETF跟踪的指数中首批"纯度"达100%的创新药指数，精准汇聚港股创新药领军 企业；中证港股通医药卫生综合指数从港股通范围内选取医药卫生行业中市值较大的50只上市公司作为 样本，覆盖创新药、医疗器械等领域。投资者可通过港股通创新药ETF易方达（159316）、港股通医药 ETF易方达（513200）等跟踪上述指数的产品，精准捕捉医药产业发展机遇。 1月30日，石药集团与阿斯利康达成总额高达185亿美元的合作，首付款12亿美元，创下中国药企对外授 权交易新纪录。2月8日，信达生物与礼来达成88.5亿美元合作，首付3.5亿美元，创新采用"端到端共 研"模式。据统计，2026年以来创新药BD合作的首付款规模，已超越2025年全年最高单季度水平，总交 易金额已达332.8亿美元，产业出海势头迅猛。 同时，龙头公司业绩预告验证了高景气度。信达生物、荣昌生物与君实生物预告2025年营业收入分别约 为110亿元、32.5亿元和25亿元，同比大幅增长45%、89%和32%，强劲的业绩增长为板块提供了坚实的 基本面支撑。 2月10日，港股医药板块全天强势领涨，截至15:15，恒生港股通创新药指数上涨2.7 ...

Core Viewpoint - Junshi Biosciences is actively developing a monkeypox recombinant protein vaccine in collaboration with several prestigious institutions, indicating a strong focus on innovative vaccine development and a commitment to expanding its product pipeline in the biopharmaceutical sector [2][3]. Company Developments - On October 27, 2023, Junshi Biosciences announced a partnership with Peking University, the Institute of Microbiology of the Chinese Academy of Sciences, Shanxi Higher Innovation Research Institute, and Beihang University to jointly develop a monkeypox recombinant protein vaccine [2]. - The company’s subsidiary, Junshi Biotech, is involved in the development of various vaccine-related products, including monkeypox and Zika vaccines, which are currently in the preclinical development stage [2]. Product Pipeline and Achievements - Junshi Biosciences has a comprehensive capability in the entire industry chain from drug discovery and development to large-scale production and commercialization, aiming to become a global innovative pharmaceutical company based in China [3]. - The company’s core product, Toripalimab, is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review. It has also received approvals in multiple countries including the U.S., EU, and Australia [3]. - The company is advancing its proprietary drug tifcemalimab, which is the first anti-BTLA monoclonal antibody to enter clinical development, with ongoing Phase III clinical trials and several Phase Ib/II studies in various tumor types [3]. Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, representing a year-on-year growth of 42.06%. However, the net profit attributable to shareholders was a loss of 596 million yuan, although this reflects a 35.72% improvement compared to the previous year [9]. Technological Advancements - The company has deployed an AI translation platform that has replaced over 80% of external translation services for scientific literature, clinical trials, and quality management, enhancing operational efficiency [4]. Market Position - As of February 10, 2023, Junshi Biosciences had a market capitalization of 36.673 billion yuan, with a trading volume of 3.32 billion yuan and a turnover rate of 1.21% [1].

从基本面看，创新药业绩预告验证产业景气。信达生物、荣昌生物和君实生物预告2025年收入约 110/32.5/25亿元，分别同比增长45%/89%/31.8% 国金证券认为，2-3月有望迎来创新药企业的业绩披露窗口，多家药企有望迎来减亏或扭亏，同时预计 2026年更多创新药企业有望扭亏并大幅释放利润；展望全年，AACR（4月）、ASCO（5月）、ESMO （10月）等学术会议上国产创新药有望进一步带来临床数据的兑现；整体上，创新药前期回调较为充 分，向上产业趋势明确，催化近期密集，继续看好板块投资机会。 港股创新药上涨，截至发稿，港股通创新药ETF易方达(159316)涨2.89%，港股通医药ETF易方达 (513200)涨2.33%。 板块反弹主要受BD交易密集落地、预告业绩高增及流动性改善三重利好驱动。 创新药重磅BD频出：石药集团×阿斯利康：1月30日达成185亿美元合作（首付12亿美元），创中国药企 BD纪录； 信达生物×礼来：2月8日达成88.5亿美元合作（首付3.5亿美元），采用"端到端共研"模式； 2026年以来创新药BD首付款规模已超25年全年最高单季度水平，总交易金额达332.8亿美元（占25 ...